Ret-Mutant Thyroid Cancer

In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed an update to the ARROW study.

The FDA granted accelerated approval to pralsetinib for treatment of certain patients with RET-altered thyroid cancer.

The FDA granted priority review to selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer, according to a press release from the agent’s manufacturer.